제약 분야 에이전틱 AI 시장 규모, 점유율, 업계 분석 보고서 : 최종사용자별, 도입 모드별, 용도별, 지역별 전망 및 예측(2026-2033년)

The Global Agentic AI In Pharmaceuticals Market is expected to reach USD 2418.1 million by 2033, growing at a CAGR of 37.3% during 2026 - 2033.

Agentic AI represents the next evolution of AI technologies, enabling autonomous reasoning, adaptive learning, intelligent workflow execution, and real-time decision-making across pharmaceutical operations. Pharmaceutical organizations are increasingly deploying agentic AI systems to accelerate drug discovery, optimize clinical trial processes, enhance regulatory compliance, improve pharmacovigilance activities, and support precision medicine initiatives.

Key Market Trends & Insights

• North America accounted for 45.51% revenue share in 2025, supported by strong pharmaceutical R&D investments, advanced AI infrastructure, and widespread adoption of intelligent drug discovery platforms.
• Large Pharmaceutical Companies represented 53.57% of market revenue in 2025 owing to significant investments in autonomous AI systems, clinical development optimization, and precision medicine initiatives.
• Cloud-Based deployment captured 50.45% share in 2025 due to increasing demand for scalable AI infrastructure, collaborative research environments, and cost-efficient computing resources.
• Clinical-Trial Design and Recruitment emerged as the leading application with 30.87% revenue share in 2025 driven by growing adoption of AI-powered patient identification, recruitment optimization, and trial management systems.
• Drug Discovery and Lead Identification accounted for 21.74% share in 2025 as pharmaceutical companies increasingly leveraged autonomous AI systems to accelerate target discovery and molecular analysis.
• Europe contributed 26.46% revenue share in 2025 supported by expanding AI-enabled pharmaceutical research, healthcare digitalization initiatives, and precision medicine investments.
• Asia Pacific captured 21.46% share in 2025 owing to rapid expansion of pharmaceutical manufacturing, biotechnology research, and AI adoption across China, Japan, India, and South Korea.
• Autonomous AI-driven drug discovery, intelligent clinical trial management, AI-powered regulatory documentation, and personalized therapeutics development are emerging as major technology trends shaping market growth.
• Increasing integration of agentic AI with genomics, multi-omics datasets, real-world evidence, and precision medicine platforms is accelerating pharmaceutical innovation globally.
• Growing emphasis on AI governance, explainability, transparency, and regulatory compliance is driving development of trusted and scalable pharmaceutical AI ecosystems.

The Agentic AI in Pharmaceuticals Market is witnessing significant momentum as pharmaceutical companies increasingly adopt autonomous AI systems capable of independently analyzing complex biomedical data, optimizing workflows, generating scientific hypotheses, and supporting critical business decisions. The ability of agentic AI to autonomously orchestrate drug discovery, clinical development, regulatory operations, manufacturing optimization, and personalized medicine initiatives is transforming traditional pharmaceutical development models. Growing investments in AI infrastructure, cloud computing, computational biology, and intelligent automation technologies are expected to further strengthen market growth as organizations seek to accelerate innovation, improve operational efficiency, and reduce development costs across the pharmaceutical value chain.

Drivers

• Accelerated Drug Development Through Autonomous Workflow Optimization
• Enhanced Regulatory Compliance via Autonomous Data Governance
• Improved Clinical Trial Efficiency Through Intelligent Patient Selection and Real-Time Data Analysis
• Scalability and Integration with Pharmaceutical Automation Infrastructure

Restraints

• Regulatory Compliance Complexity and Uncertainty
• High Implementation and Operational Costs
• Technical Limitations in Trust, Transparency, and Data Integration

Opportunities

• Advanced Autonomous Drug Discovery and Development Optimization
• Intelligent Pharmaceutical Supply Chain and Manufacturing Automation
• Next-Generation Personalized Therapeutics and Adaptive Treatment Protocols

Challenges

• Regulatory Compliance and Legal Uncertainty
• Data Privacy and Security Vulnerabilities
• High Implementation Costs and Technological Integration Barriers

Market Share Analysis

Recursion Pharmaceuticals, Inc., Shenzhen Jingtai Technology Co., Ltd. (XtalPi), InSilico Medicine, and Schrodinger, LLC are among the leading participants in the market. Other key companies include Owkin Inc., BenevolentAI Group, PeptiDream Inc., Deep Genomics Incorporated, Healx Limited, and Numerion Labs, Inc.

Competition is centered on autonomous drug discovery platforms, AI-native pharmaceutical R&D ecosystems, computational biology, multimodal biological data integration, and AI-enabled clinical development capabilities. Companies are increasingly focusing on AI infrastructure expansion, strategic collaborations, biological intelligence platforms, autonomous research systems, and precision medicine innovation.

End User Outlook

Based on End User, the market is segmented into Large Pharmaceutical Companies, Small and Mid-Size Biotech Firms, Contract Research Organizations, and Academic and Research Institutes.

The Large Pharmaceutical Companies market dominated the Global Agentic AI In Pharmaceuticals Market by End User in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 1248.5 million by 2033, growing at a CAGR of 36.7% during the forecast period. The Small and Mid-Size Biotech Firms market is expected to witness a CAGR of 36.6% during (2026 - 2033). Additionally, The Contract Research Organizations market is expected to witness highest CAGR of 38.1% during (2026 - 2033).

Large Pharmaceutical Companies dominated the market in 2025 driven by increasing investments in autonomous AI technologies to accelerate drug discovery, optimize clinical development, improve precision medicine initiatives, and strengthen operational efficiency across pharmaceutical value chains. These organizations increasingly deploy agentic AI systems capable of autonomous reasoning, workflow automation, predictive modeling, and intelligent decision-making to support complex research and development activities.

Small and Mid-Size Biotech Firms are also witnessing strong adoption due to growing accessibility of cloud-based AI platforms, increasing biotechnology innovation, and rising demand for efficient drug discovery solutions. Contract Research Organizations are utilizing agentic AI technologies to improve clinical trial management, patient recruitment, data analysis, and outsourced pharmaceutical research operations. Academic and Research Institutes continue expanding adoption of advanced AI-driven scientific research systems to accelerate pharmaceutical innovation and biomedical discovery activities.

Deployment Mode Outlook

Based on Deployment Mode, the market is segmented into Cloud-Based, Hybrid, and On-Premise.

The Cloud-Based market dominated the Global Agentic AI In Pharmaceuticals Market by Deployment Mode in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 1173.1 million by 2033, growing at a CAGR of 36.6 % during the forecast period. The Hybrid market is expected to witness a CAGR of 37.9% during (2026 - 2033).

Pharmaceutical companies increasingly utilize cloud-based platforms to support high-volume data processing, AI model training, and global research collaboration activities. Hybrid deployment is witnessing significant growth as organizations seek to balance cloud scalability with data security, regulatory compliance, and operational control. On-Premise deployment remains important among organizations handling sensitive intellectual property, proprietary molecular datasets, and regulated clinical information requiring enhanced cybersecurity and direct infrastructure management.

Application Outlook

Based on Application, the market is segmented into Clinical-Trial Design and Recruitment, Drug Discovery and Lead Identification, Lead Optimization, Pharmacovigilance and Safety Monitoring, Pre-clinical Development, Manufacturing-Process Optimization, and Other Applications.

Drug Discovery and Lead Identification continues witnessing strong adoption as pharmaceutical organizations increasingly leverage agentic AI platforms for molecular analysis, target discovery, and therapeutic innovation. Lead Optimization is expanding due to growing utilization of predictive analytics and molecular simulation technologies. Pharmacovigilance and Safety Monitoring adoption is increasing as organizations seek automated adverse event detection and regulatory reporting capabilities. Pre-clinical Development, Manufacturing-Process Optimization, and Other Applications are also experiencing significant growth driven by expanding AI integration across pharmaceutical research, manufacturing, compliance, and commercial operations.

Regional Outlook

Region-wise, the Agentic AI in Pharmaceuticals Market is analyzed across North America, Europe, Asia Pacific, and LAMEA.

The North America market dominated the Global Agentic AI In Pharmaceuticals Market by Region in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 1065.6 million by 2033, growing at a CAGR of 36.7 % during the forecast period.The Asia Pacific market is expected to witness a CAGR of 38.2% during (2026 - 2033).

North America dominated the market in 2025 supported by strong pharmaceutical R&D investments, advanced AI infrastructure, robust healthcare data availability, and widespread adoption of intelligent drug discovery platforms. Europe continues witnessing substantial growth driven by increasing healthcare digitalization, precision medicine initiatives, and AI-enabled pharmaceutical innovation. Asia Pacific is emerging as a high-growth region owing to rapid expansion of biotechnology research, pharmaceutical manufacturing, and AI adoption across major economies.

Agentic AI in Pharmaceuticals Market Coverage

Recent Strategies Deployed in the Market

• BenevolentAI refocused its business strategy to strengthen AI-driven drug discovery operations, autonomous research systems, predictive biology platforms, and intelligent pharmaceutical development capabilities.
• Cyient Semiconductors expanded investments in advanced semiconductor engineering and AI infrastructure capabilities supporting high-performance computing environments for pharmaceutical AI applications.
• Owkin launched advanced AI infrastructure designed to support biological discovery, predictive modeling, therapeutic innovation, and next-generation AI scientist systems.
• Healx advanced its AI-created drug development pipeline focused on rare diseases and oncology therapeutics through intelligent drug discovery and autonomous pharmaceutical development platforms.
• Deep Genomics strengthened its AI-enabled genomic medicine ecosystem through expanded scientific advisory capabilities, genomic intelligence platforms, and computational therapeutic development initiatives.
• Numerion Labs expanded AI-powered drug discovery and research automation technologies focused on computational intelligence, autonomous experimentation, and pharmaceutical innovation acceleration.
• Owkin entered a multi-year licensing agreement to develop advanced AI agents supporting biomedical research, autonomous scientific discovery, and pharmaceutical innovation workflows.
• PeptiDream and Merck established a strategic collaboration focused on peptide drug conjugate development supported by advanced computational intelligence and therapeutic discovery technologies.
• ICON plc expanded artificial intelligence capabilities through innovation initiatives supporting clinical trial automation, predictive analytics, and intelligent research management systems.
• Owkin expanded international AI drug development and biological intelligence operations through broader deployment of AI-enabled pharmaceutical research systems and global collaboration initiatives.

List of Key Companies Profiled

• InSilico Medicine
• Numerion Labs, Inc.
• BenevolentAI Group
• Shenzhen Jingtai Technology Co., Ltd. (XtalPi)
• Recursion Pharmaceuticals, Inc.
• Deep Genomics Incorporated
• Schrodinger, LLC
• Owkin Inc.
• PeptiDream Inc.
• Healx Limited

Global Agentic AI in Pharmaceuticals Market Report Segmentation

By End User

• Large Pharmaceutical Companies
• Small and Mid-Size Biotech Firms
• Contract Research Organizations
• Academic and Research Institutes

By Deployment Mode

• Cloud-Based
• Hybrid
• On-Premise

By Application

• Clinical-Trial Design and Recruitment
• Drug Discovery and Lead Identification
• Lead Optimization
• Pharmacovigilance and Safety Monitoring
• Pre-clinical Development
• Manufacturing-Process Optimization
• Other Applications

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Research Scope & Methodology

• 1.1 Market Definition
• 1.2 Analysis Period & Currency
• 1.3 Segmentation
  • 1.3.1 Agentic AI In Pharmaceuticals Market, by End User
  • 1.3.2 Agentic AI In Pharmaceuticals Market, by Deployment Mode
  • 1.3.3 Agentic AI In Pharmaceuticals Market, by Application
  • 1.3.4 Agentic AI In Pharmaceuticals Market, by Geography
• 1.4 Research Methodology

Chapter 2. Market Overview

• 2.1 COVID-19 Impact
• 2.2 Market Composition and Scenario

Chapter 3. Key Factors Impacting Market

• 3.1 Market Drivers
• 3.2 Market Restraints
• 3.3 Market Opportunities
• 3.4 Market Challenges
• 3.5 Market Trends
• 3.6 State of Competition
• 3.7 Market Consolidation
• 3.8 Key Customer Criteria

Chapter 4. Product Life Cycle

Chapter 5. Value Chain Analysis of Agentic AI In Pharmaceuticals Market

Chapter 6. Competition Analysis - Global

• 6.1 Market Share Analysis
• 6.2 Recent Developments and Strategies
  • 6.2.1 Mergers & Acquisitions
  • 6.2.2 Product Launch & Product Expansion
  • 6.2.3 Partnership, Collaboration & Agreements
  • 6.2.4 Geographical Expansion

Chapter 7. Segmentation By End User

• 7.1 Large Pharmaceutical Companies
• 7.2 Small and Mid-Size Biotech Firms
• 7.3 Contract Research Organizations
• 7.4 Academic and Research Institutes

Chapter 8. Segmentation By Deployment Mode

• 8.1 Cloud-Based
• 8.2 Hybrid
• 8.3 On-Premise

Chapter 9. Segmentation By Application

• 9.1 Clinical-Trial Design and Recruitment
• 9.2 Drug Discovery and Lead Identification
• 9.3 Lead Optimization
• 9.4 Pharmacovigilance and Safety Monitoring
• 9.5 Pre-clinical Development
• 9.6 Manufacturing-Process Optimization
• 9.7 Other Application

Chapter 10. North America Market

• 10.1 Market Overview
• 10.2 Key Factors Impacting Market
  • 10.2.1 Market Drivers
  • 10.2.2 Market Restraints
  • 10.2.3 Market Opportunities
  • 10.2.4 Market Challenges
  • 10.2.5 Market Trends
  • 10.2.6 State of Competition
  • 10.2.7 Market Consolidation
  • 10.2.8 Key Customer Criteria
• 10.3 Product Life Cycle
• 10.4 Segmentation By End User
  • 10.4.1 Large Pharmaceutical Companies
  • 10.4.2 Small and Mid-Size Biotech Firms
  • 10.4.3 Contract Research Organizations
  • 10.4.4 Academic and Research Institutes
• 10.5 Segmentation By Deployment Mode
  • 10.5.1 Cloud-Based
  • 10.5.2 Hybrid
  • 10.5.3 On-Premise
• 10.6 Segmentation By Application
  • 10.6.1 Clinical-Trial Design and Recruitment
  • 10.6.2 Drug Discovery and Lead Identification
  • 10.6.3 Lead Optimization
  • 10.6.4 Pharmacovigilance and Safety Monitoring
  • 10.6.5 Pre-clinical Development
  • 10.6.6 Manufacturing-Process Optimization
  • 10.6.7 Other Application
• 10.7 Segmentation By Country
  • 10.7.1 US
    • 10.7.1.1 Segmentation By End User
      • 10.7.1.1.1 Large Pharmaceutical Companies
      • 10.7.1.1.2 Small and Mid-Size Biotech Firms
      • 10.7.1.1.3 Contract Research Organizations
      • 10.7.1.1.4 Academic and Research Institutes
    • 10.7.1.2 Segmentation By Deployment Mode
      • 10.7.1.2.1 Cloud-Based
      • 10.7.1.2.2 Hybrid
      • 10.7.1.2.3 On-Premise
    • 10.7.1.3 Segmentation By Application
      • 10.7.1.3.1 Clinical-Trial Design and Recruitment
      • 10.7.1.3.2 Drug Discovery and Lead Identification
      • 10.7.1.3.3 Lead Optimization
      • 10.7.1.3.4 Pharmacovigilance and Safety Monitoring
      • 10.7.1.3.5 Pre-clinical Development
      • 10.7.1.3.6 Manufacturing-Process Optimization
      • 10.7.1.3.7 Other Application
  • 10.7.2 Canada
    • 10.7.2.1 Segmentation By End User
      • 10.7.2.1.1 Large Pharmaceutical Companies
      • 10.7.2.1.2 Small and Mid-Size Biotech Firms
      • 10.7.2.1.3 Contract Research Organizations
      • 10.7.2.1.4 Academic and Research Institutes
    • 10.7.2.2 Segmentation By Deployment Mode
      • 10.7.2.2.1 Cloud-Based
      • 10.7.2.2.2 Hybrid
      • 10.7.2.2.3 On-Premise
    • 10.7.2.3 Segmentation By Application
      • 10.7.2.3.1 Clinical-Trial Design and Recruitment
      • 10.7.2.3.2 Drug Discovery and Lead Identification
      • 10.7.2.3.3 Lead Optimization
      • 10.7.2.3.4 Pharmacovigilance and Safety Monitoring
      • 10.7.2.3.5 Pre-clinical Development
      • 10.7.2.3.6 Manufacturing-Process Optimization
      • 10.7.2.3.7 Other Application
  • 10.7.3 Mexico
    • 10.7.3.1 Segmentation By End User
      • 10.7.3.1.1 Large Pharmaceutical Companies
      • 10.7.3.1.2 Small and Mid-Size Biotech Firms
      • 10.7.3.1.3 Contract Research Organizations
      • 10.7.3.1.4 Academic and Research Institutes
    • 10.7.3.2 Segmentation By Deployment Mode
      • 10.7.3.2.1 Cloud-Based
      • 10.7.3.2.2 Hybrid
      • 10.7.3.2.3 On-Premise
    • 10.7.3.3 Segmentation By Application
      • 10.7.3.3.1 Clinical-Trial Design and Recruitment
      • 10.7.3.3.2 Drug Discovery and Lead Identification
      • 10.7.3.3.3 Lead Optimization
      • 10.7.3.3.4 Pharmacovigilance and Safety Monitoring
      • 10.7.3.3.5 Pre-clinical Development
      • 10.7.3.3.6 Manufacturing-Process Optimization
      • 10.7.3.3.7 Other Application
  • 10.7.4 Rest of North America
    • 10.7.4.1 Segmentation By End User
      • 10.7.4.1.1 Large Pharmaceutical Companies
      • 10.7.4.1.2 Small and Mid-Size Biotech Firms
      • 10.7.4.1.3 Contract Research Organizations
      • 10.7.4.1.4 Academic and Research Institutes
    • 10.7.4.2 Segmentation By Deployment Mode
      • 10.7.4.2.1 Cloud-Based
      • 10.7.4.2.2 Hybrid
      • 10.7.4.2.3 On-Premise
    • 10.7.4.3 Segmentation By Application
      • 10.7.4.3.1 Clinical-Trial Design and Recruitment
      • 10.7.4.3.2 Drug Discovery and Lead Identification
      • 10.7.4.3.3 Lead Optimization
      • 10.7.4.3.4 Pharmacovigilance and Safety Monitoring
      • 10.7.4.3.5 Pre-clinical Development
      • 10.7.4.3.6 Manufacturing-Process Optimization
      • 10.7.4.3.7 Other Application

Chapter 11. Europe Market

• 11.1 Market Overview
• 11.2 Key Factors Impacting Market
  • 11.2.1 Market Drivers
  • 11.2.2 Market Restraints
  • 11.2.3 Market Opportunities
  • 11.2.4 Market Challenges
  • 11.2.5 Market Trends
  • 11.2.6 State of Competition
  • 11.2.7 Market Consolidation
  • 11.2.8 Key Customer Criteria
• 11.3 Product Life Cycle
• 11.4 Segmentation By End User
  • 11.4.1 Large Pharmaceutical Companies
  • 11.4.2 Small and Mid-Size Biotech Firms
  • 11.4.3 Contract Research Organizations
  • 11.4.4 Academic and Research Institutes
• 11.5 Segmentation By Deployment Mode
  • 11.5.1 Cloud-Based
  • 11.5.2 Hybrid
  • 11.5.3 On-Premise
• 11.6 Segmentation By Application
  • 11.6.1 Clinical-Trial Design and Recruitment
  • 11.6.2 Drug Discovery and Lead Identification
  • 11.6.3 Lead Optimization
  • 11.6.4 Pharmacovigilance and Safety Monitoring
  • 11.6.5 Pre-clinical Development
  • 11.6.6 Manufacturing-Process Optimization
  • 11.6.7 Other Application
• 11.7 Segmentation By Country
  • 11.7.1 Germany
    • 11.7.1.1 Segmentation By End User
      • 11.7.1.1.1 Large Pharmaceutical Companies
      • 11.7.1.1.2 Small and Mid-Size Biotech Firms
      • 11.7.1.1.3 Contract Research Organizations
      • 11.7.1.1.4 Academic and Research Institutes
    • 11.7.1.2 Segmentation By Deployment Mode
      • 11.7.1.2.1 Cloud-Based
      • 11.7.1.2.2 Hybrid
      • 11.7.1.2.3 On-Premise
    • 11.7.1.3 Segmentation By Application
      • 11.7.1.3.1 Clinical-Trial Design and Recruitment
      • 11.7.1.3.2 Drug Discovery and Lead Identification
      • 11.7.1.3.3 Lead Optimization
      • 11.7.1.3.4 Pharmacovigilance and Safety Monitoring
      • 11.7.1.3.5 Pre-clinical Development
      • 11.7.1.3.6 Manufacturing-Process Optimization
      • 11.7.1.3.7 Other Application
  • 11.7.2 UK
    • 11.7.2.1 Segmentation By End User
      • 11.7.2.1.1 Large Pharmaceutical Companies
      • 11.7.2.1.2 Small and Mid-Size Biotech Firms
      • 11.7.2.1.3 Contract Research Organizations
      • 11.7.2.1.4 Academic and Research Institutes
    • 11.7.2.2 Segmentation By Deployment Mode
      • 11.7.2.2.1 Cloud-Based
      • 11.7.2.2.2 Hybrid
      • 11.7.2.2.3 On-Premise
    • 11.7.2.3 Segmentation By Application
      • 11.7.2.3.1 Clinical-Trial Design and Recruitment
      • 11.7.2.3.2 Drug Discovery and Lead Identification
      • 11.7.2.3.3 Lead Optimization
      • 11.7.2.3.4 Pharmacovigilance and Safety Monitoring
      • 11.7.2.3.5 Pre-clinical Development
      • 11.7.2.3.6 Manufacturing-Process Optimization
      • 11.7.2.3.7 Other Application
  • 11.7.3 France
    • 11.7.3.1 Segmentation By End User
      • 11.7.3.1.1 Large Pharmaceutical Companies
      • 11.7.3.1.2 Small and Mid-Size Biotech Firms
      • 11.7.3.1.3 Contract Research Organizations
      • 11.7.3.1.4 Academic and Research Institutes
    • 11.7.3.2 Segmentation By Deployment Mode
      • 11.7.3.2.1 Cloud-Based
      • 11.7.3.2.2 Hybrid
      • 11.7.3.2.3 On-Premise
    • 11.7.3.3 Segmentation By Application
      • 11.7.3.3.1 Clinical-Trial Design and Recruitment
      • 11.7.3.3.2 Drug Discovery and Lead Identification
      • 11.7.3.3.3 Lead Optimization
      • 11.7.3.3.4 Pharmacovigilance and Safety Monitoring
      • 11.7.3.3.5 Pre-clinical Development
      • 11.7.3.3.6 Manufacturing-Process Optimization
      • 11.7.3.3.7 Other Application
  • 11.7.4 Russia
    • 11.7.4.1 Segmentation By End User
      • 11.7.4.1.1 Large Pharmaceutical Companies
      • 11.7.4.1.2 Small and Mid-Size Biotech Firms
      • 11.7.4.1.3 Contract Research Organizations
      • 11.7.4.1.4 Academic and Research Institutes
    • 11.7.4.2 Segmentation By Deployment Mode
      • 11.7.4.2.1 Cloud-Based
      • 11.7.4.2.2 Hybrid
      • 11.7.4.2.3 On-Premise
    • 11.7.4.3 Segmentation By Application
      • 11.7.4.3.1 Clinical-Trial Design and Recruitment
      • 11.7.4.3.2 Drug Discovery and Lead Identification
      • 11.7.4.3.3 Lead Optimization
      • 11.7.4.3.4 Pharmacovigilance and Safety Monitoring
      • 11.7.4.3.5 Pre-clinical Development
      • 11.7.4.3.6 Manufacturing-Process Optimization
      • 11.7.4.3.7 Other Application
  • 11.7.5 Spain
    • 11.7.5.1 Segmentation By End User
      • 11.7.5.1.1 Large Pharmaceutical Companies
      • 11.7.5.1.2 Small and Mid-Size Biotech Firms
      • 11.7.5.1.3 Contract Research Organizations
      • 11.7.5.1.4 Academic and Research Institutes
    • 11.7.5.2 Segmentation By Deployment Mode
      • 11.7.5.2.1 Cloud-Based
      • 11.7.5.2.2 Hybrid
      • 11.7.5.2.3 On-Premise
    • 11.7.5.3 Segmentation By Application
      • 11.7.5.3.1 Clinical-Trial Design and Recruitment
      • 11.7.5.3.2 Drug Discovery and Lead Identification
      • 11.7.5.3.3 Lead Optimization
      • 11.7.5.3.4 Pharmacovigilance and Safety Monitoring
      • 11.7.5.3.5 Pre-clinical Development
      • 11.7.5.3.6 Manufacturing-Process Optimization
      • 11.7.5.3.7 Other Application
  • 11.7.6 Italy
    • 11.7.6.1 Segmentation By End User
      • 11.7.6.1.1 Large Pharmaceutical Companies
      • 11.7.6.1.2 Small and Mid-Size Biotech Firms
      • 11.7.6.1.3 Contract Research Organizations
      • 11.7.6.1.4 Academic and Research Institutes
    • 11.7.6.2 Segmentation By Deployment Mode
      • 11.7.6.2.1 Cloud-Based
      • 11.7.6.2.2 Hybrid
      • 11.7.6.2.3 On-Premise
    • 11.7.6.3 Segmentation By Application
      • 11.7.6.3.1 Clinical-Trial Design and Recruitment
      • 11.7.6.3.2 Drug Discovery and Lead Identification
      • 11.7.6.3.3 Lead Optimization
      • 11.7.6.3.4 Pharmacovigilance and Safety Monitoring
      • 11.7.6.3.5 Pre-clinical Development
      • 11.7.6.3.6 Manufacturing-Process Optimization
      • 11.7.6.3.7 Other Application
  • 11.7.7 Rest of Europe
    • 11.7.7.1 Segmentation By End User
      • 11.7.7.1.1 Large Pharmaceutical Companies
      • 11.7.7.1.2 Small and Mid-Size Biotech Firms
      • 11.7.7.1.3 Contract Research Organizations
      • 11.7.7.1.4 Academic and Research Institutes
    • 11.7.7.2 Segmentation By Deployment Mode
      • 11.7.7.2.1 Cloud-Based
      • 11.7.7.2.2 Hybrid
      • 11.7.7.2.3 On-Premise
    • 11.7.7.3 Segmentation By Application
      • 11.7.7.3.1 Clinical-Trial Design and Recruitment
      • 11.7.7.3.2 Drug Discovery and Lead Identification
      • 11.7.7.3.3 Lead Optimization
      • 11.7.7.3.4 Pharmacovigilance and Safety Monitoring
      • 11.7.7.3.5 Pre-clinical Development
      • 11.7.7.3.6 Manufacturing-Process Optimization
      • 11.7.7.3.7 Other Application

Chapter 12. Asia Pacific Market

• 12.1 Market Overview
• 12.2 Key Factors Impacting Market
  • 12.2.1 Market Drivers
  • 12.2.2 Market Restraints
  • 12.2.3 Market Opportunities
  • 12.2.4 Market Challenges
  • 12.2.5 Market Trends
  • 12.2.6 State of Competition
  • 12.2.7 Market Consolidation
  • 12.2.8 Key Customer Criteria
• 12.3 Product Life Cycle
• 12.4 Segmentation By End User
  • 12.4.1 Large Pharmaceutical Companies
  • 12.4.2 Small and Mid-Size Biotech Firms
  • 12.4.3 Contract Research Organizations
  • 12.4.4 Academic and Research Institutes
• 12.5 Segmentation By Deployment Mode
  • 12.5.1 Cloud-Based
  • 12.5.2 Hybrid
  • 12.5.3 On-Premise
• 12.6 Segmentation By Application
  • 12.6.1 Clinical-Trial Design and Recruitment
  • 12.6.2 Drug Discovery and Lead Identification
  • 12.6.3 Lead Optimization
  • 12.6.4 Pharmacovigilance and Safety Monitoring
  • 12.6.5 Pre-clinical Development
  • 12.6.6 Manufacturing-Process Optimization
  • 12.6.7 Other Application
• 12.7 Segmentation By Country
  • 12.7.1 China
    • 12.7.1.1 Segmentation By End User
      • 12.7.1.1.1 Large Pharmaceutical Companies
      • 12.7.1.1.2 Small and Mid-Size Biotech Firms
      • 12.7.1.1.3 Contract Research Organizations
      • 12.7.1.1.4 Academic and Research Institutes
    • 12.7.1.2 Segmentation By Deployment Mode
      • 12.7.1.2.1 Cloud-Based
      • 12.7.1.2.2 Hybrid
      • 12.7.1.2.3 On-Premise
    • 12.7.1.3 Segmentation By Application
      • 12.7.1.3.1 Clinical-Trial Design and Recruitment
      • 12.7.1.3.2 Drug Discovery and Lead Identification
      • 12.7.1.3.3 Lead Optimization
      • 12.7.1.3.4 Pharmacovigilance and Safety Monitoring
      • 12.7.1.3.5 Pre-clinical Development
      • 12.7.1.3.6 Manufacturing-Process Optimization
      • 12.7.1.3.7 Other Application
  • 12.7.2 Japan
    • 12.7.2.1 Segmentation By End User
      • 12.7.2.1.1 Large Pharmaceutical Companies
      • 12.7.2.1.2 Small and Mid-Size Biotech Firms
      • 12.7.2.1.3 Contract Research Organizations
      • 12.7.2.1.4 Academic and Research Institutes
    • 12.7.2.2 Segmentation By Deployment Mode
      • 12.7.2.2.1 Cloud-Based
      • 12.7.2.2.2 Hybrid
      • 12.7.2.2.3 On-Premise
    • 12.7.2.3 Segmentation By Application
      • 12.7.2.3.1 Clinical-Trial Design and Recruitment
      • 12.7.2.3.2 Drug Discovery and Lead Identification
      • 12.7.2.3.3 Lead Optimization
      • 12.7.2.3.4 Pharmacovigilance and Safety Monitoring
      • 12.7.2.3.5 Pre-clinical Development
      • 12.7.2.3.6 Manufacturing-Process Optimization
      • 12.7.2.3.7 Other Application
  • 12.7.3 India
    • 12.7.3.1 Segmentation By End User
      • 12.7.3.1.1 Large Pharmaceutical Companies
      • 12.7.3.1.2 Small and Mid-Size Biotech Firms
      • 12.7.3.1.3 Contract Research Organizations
      • 12.7.3.1.4 Academic and Research Institutes
    • 12.7.3.2 Segmentation By Deployment Mode
      • 12.7.3.2.1 Cloud-Based
      • 12.7.3.2.2 Hybrid
      • 12.7.3.2.3 On-Premise
    • 12.7.3.3 Segmentation By Application
      • 12.7.3.3.1 Clinical-Trial Design and Recruitment
      • 12.7.3.3.2 Drug Discovery and Lead Identification
      • 12.7.3.3.3 Lead Optimization
      • 12.7.3.3.4 Pharmacovigilance and Safety Monitoring
      • 12.7.3.3.5 Pre-clinical Development
      • 12.7.3.3.6 Manufacturing-Process Optimization
      • 12.7.3.3.7 Other Application
  • 12.7.4 South Korea
    • 12.7.4.1 Segmentation By End User
      • 12.7.4.1.1 Large Pharmaceutical Companies
      • 12.7.4.1.2 Small and Mid-Size Biotech Firms
      • 12.7.4.1.3 Contract Research Organizations
      • 12.7.4.1.4 Academic and Research Institutes
    • 12.7.4.2 Segmentation By Deployment Mode
      • 12.7.4.2.1 Cloud-Based
      • 12.7.4.2.2 Hybrid
      • 12.7.4.2.3 On-Premise
    • 12.7.4.3 Segmentation By Application
      • 12.7.4.3.1 Clinical-Trial Design and Recruitment
      • 12.7.4.3.2 Drug Discovery and Lead Identification
      • 12.7.4.3.3 Lead Optimization
      • 12.7.4.3.4 Pharmacovigilance and Safety Monitoring
      • 12.7.4.3.5 Pre-clinical Development
      • 12.7.4.3.6 Manufacturing-Process Optimization
      • 12.7.4.3.7 Other Application
  • 12.7.5 Australia
    • 12.7.5.1 Segmentation By End User
      • 12.7.5.1.1 Large Pharmaceutical Companies
      • 12.7.5.1.2 Small and Mid-Size Biotech Firms
      • 12.7.5.1.3 Contract Research Organizations
      • 12.7.5.1.4 Academic and Research Institutes
    • 12.7.5.2 Segmentation By Deployment Mode
      • 12.7.5.2.1 Cloud-Based
      • 12.7.5.2.2 Hybrid
      • 12.7.5.2.3 On-Premise
    • 12.7.5.3 Segmentation By Application
      • 12.7.5.3.1 Clinical-Trial Design and Recruitment
      • 12.7.5.3.2 Drug Discovery and Lead Identification
      • 12.7.5.3.3 Lead Optimization
      • 12.7.5.3.4 Pharmacovigilance and Safety Monitoring
      • 12.7.5.3.5 Pre-clinical Development
      • 12.7.5.3.6 Manufacturing-Process Optimization
      • 12.7.5.3.7 Other Application
  • 12.7.6 Malaysia
    • 12.7.6.1 Segmentation By End User
      • 12.7.6.1.1 Large Pharmaceutical Companies
      • 12.7.6.1.2 Small and Mid-Size Biotech Firms
      • 12.7.6.1.3 Contract Research Organizations
      • 12.7.6.1.4 Academic and Research Institutes
    • 12.7.6.2 Segmentation By Deployment Mode
      • 12.7.6.2.1 Cloud-Based
      • 12.7.6.2.2 Hybrid
      • 12.7.6.2.3 On-Premise
    • 12.7.6.3 Segmentation By Application
      • 12.7.6.3.1 Clinical-Trial Design and Recruitment
      • 12.7.6.3.2 Drug Discovery and Lead Identification
      • 12.7.6.3.3 Lead Optimization
      • 12.7.6.3.4 Pharmacovigilance and Safety Monitoring
      • 12.7.6.3.5 Pre-clinical Development
      • 12.7.6.3.6 Manufacturing-Process Optimization
      • 12.7.6.3.7 Other Application
  • 12.7.7 Rest of Asia Pacific
    • 12.7.7.1 Segmentation By End User
      • 12.7.7.1.1 Large Pharmaceutical Companies
      • 12.7.7.1.2 Small and Mid-Size Biotech Firms
      • 12.7.7.1.3 Contract Research Organizations
      • 12.7.7.1.4 Academic and Research Institutes
    • 12.7.7.2 Segmentation By Deployment Mode
      • 12.7.7.2.1 Cloud-Based
      • 12.7.7.2.2 Hybrid
      • 12.7.7.2.3 On-Premise
    • 12.7.7.3 Segmentation By Application
      • 12.7.7.3.1 Clinical-Trial Design and Recruitment
      • 12.7.7.3.2 Drug Discovery and Lead Identification
      • 12.7.7.3.3 Lead Optimization
      • 12.7.7.3.4 Pharmacovigilance and Safety Monitoring
      • 12.7.7.3.5 Pre-clinical Development
      • 12.7.7.3.6 Manufacturing-Process Optimization
      • 12.7.7.3.7 Other Application

Chapter 13. LAMEA Market

• 13.1 Market Overview
• 13.2 Key Factors Impacting Market
  • 13.2.1 Market Drivers
  • 13.2.2 Market Restraints
  • 13.2.3 Market Opportunities
  • 13.2.4 Market Challenges
  • 13.2.5 Market Trends
  • 13.2.6 State of Competition
  • 13.2.7 Market Consolidation
  • 13.2.8 Key Customer Criteria
• 13.3 Product Life Cycle
• 13.4 Segmentation By End User
  • 13.4.1 Large Pharmaceutical Companies
  • 13.4.2 Small and Mid-Size Biotech Firms
  • 13.4.3 Contract Research Organizations
  • 13.4.4 Academic and Research Institutes
• 13.5 Segmentation By Deployment Mode
  • 13.5.1 Cloud-Based
  • 13.5.2 Hybrid
  • 13.5.3 On-Premise
• 13.6 Segmentation By Application
  • 13.6.1 Clinical-Trial Design and Recruitment
  • 13.6.2 Drug Discovery and Lead Identification
  • 13.6.3 Lead Optimization
  • 13.6.4 Pharmacovigilance and Safety Monitoring
  • 13.6.5 Pre-clinical Development
  • 13.6.6 Manufacturing-Process Optimization
  • 13.6.7 Other Application
• 13.7 Segmentation By Country
  • 13.7.1 Brazil
    • 13.7.1.1 Segmentation By End User
      • 13.7.1.1.1 Large Pharmaceutical Companies
      • 13.7.1.1.2 Small and Mid-Size Biotech Firms
      • 13.7.1.1.3 Contract Research Organizations
      • 13.7.1.1.4 Academic and Research Institutes
    • 13.7.1.2 Segmentation By Deployment Mode
      • 13.7.1.2.1 Cloud-Based
      • 13.7.1.2.2 Hybrid
      • 13.7.1.2.3 On-Premise
    • 13.7.1.3 Segmentation By Application
      • 13.7.1.3.1 Clinical-Trial Design and Recruitment
      • 13.7.1.3.2 Drug Discovery and Lead Identification
      • 13.7.1.3.3 Lead Optimization
      • 13.7.1.3.4 Pharmacovigilance and Safety Monitoring
      • 13.7.1.3.5 Pre-clinical Development
      • 13.7.1.3.6 Manufacturing-Process Optimization
      • 13.7.1.3.7 Other Application
  • 13.7.2 Argentina
    • 13.7.2.1 Segmentation By End User
      • 13.7.2.1.1 Large Pharmaceutical Companies
      • 13.7.2.1.2 Small and Mid-Size Biotech Firms
      • 13.7.2.1.3 Contract Research Organizations
      • 13.7.2.1.4 Academic and Research Institutes
    • 13.7.2.2 Segmentation By Deployment Mode
      • 13.7.2.2.1 Cloud-Based
      • 13.7.2.2.2 Hybrid
      • 13.7.2.2.3 On-Premise
    • 13.7.2.3 Segmentation By Application
      • 13.7.2.3.1 Clinical-Trial Design and Recruitment
      • 13.7.2.3.2 Drug Discovery and Lead Identification
      • 13.7.2.3.3 Lead Optimization
      • 13.7.2.3.4 Pharmacovigilance and Safety Monitoring
      • 13.7.2.3.5 Pre-clinical Development
      • 13.7.2.3.6 Manufacturing-Process Optimization
      • 13.7.2.3.7 Other Application
  • 13.7.3 UAE
    • 13.7.3.1 Segmentation By End User
      • 13.7.3.1.1 Large Pharmaceutical Companies
      • 13.7.3.1.2 Small and Mid-Size Biotech Firms
      • 13.7.3.1.3 Contract Research Organizations
      • 13.7.3.1.4 Academic and Research Institutes
    • 13.7.3.2 Segmentation By Deployment Mode
      • 13.7.3.2.1 Cloud-Based
      • 13.7.3.2.2 Hybrid
      • 13.7.3.2.3 On-Premise
    • 13.7.3.3 Segmentation By Application
      • 13.7.3.3.1 Clinical-Trial Design and Recruitment
      • 13.7.3.3.2 Drug Discovery and Lead Identification
      • 13.7.3.3.3 Lead Optimization
      • 13.7.3.3.4 Pharmacovigilance and Safety Monitoring
      • 13.7.3.3.5 Pre-clinical Development
      • 13.7.3.3.6 Manufacturing-Process Optimization
      • 13.7.3.3.7 Other Application
  • 13.7.4 Saudi Arabia
    • 13.7.4.1 Segmentation By End User
      • 13.7.4.1.1 Large Pharmaceutical Companies
      • 13.7.4.1.2 Small and Mid-Size Biotech Firms
      • 13.7.4.1.3 Contract Research Organizations
      • 13.7.4.1.4 Academic and Research Institutes
    • 13.7.4.2 Segmentation By Deployment Mode
      • 13.7.4.2.1 Cloud-Based
      • 13.7.4.2.2 Hybrid
      • 13.7.4.2.3 On-Premise
    • 13.7.4.3 Segmentation By Application
      • 13.7.4.3.1 Clinical-Trial Design and Recruitment
      • 13.7.4.3.2 Drug Discovery and Lead Identification
      • 13.7.4.3.3 Lead Optimization
      • 13.7.4.3.4 Pharmacovigilance and Safety Monitoring
      • 13.7.4.3.5 Pre-clinical Development
      • 13.7.4.3.6 Manufacturing-Process Optimization
      • 13.7.4.3.7 Other Application
  • 13.7.5 South Africa
    • 13.7.5.1 Segmentation By End User
      • 13.7.5.1.1 Large Pharmaceutical Companies
      • 13.7.5.1.2 Small and Mid-Size Biotech Firms
      • 13.7.5.1.3 Contract Research Organizations
      • 13.7.5.1.4 Academic and Research Institutes
    • 13.7.5.2 Segmentation By Deployment Mode
      • 13.7.5.2.1 Cloud-Based
      • 13.7.5.2.2 Hybrid
      • 13.7.5.2.3 On-Premise
    • 13.7.5.3 Segmentation By Application
      • 13.7.5.3.1 Clinical-Trial Design and Recruitment
      • 13.7.5.3.2 Drug Discovery and Lead Identification
      • 13.7.5.3.3 Lead Optimization
      • 13.7.5.3.4 Pharmacovigilance and Safety Monitoring
      • 13.7.5.3.5 Pre-clinical Development
      • 13.7.5.3.6 Manufacturing-Process Optimization
      • 13.7.5.3.7 Other Application
  • 13.7.6 Nigeria
    • 13.7.6.1 Segmentation By End User
      • 13.7.6.1.1 Large Pharmaceutical Companies
      • 13.7.6.1.2 Small and Mid-Size Biotech Firms
      • 13.7.6.1.3 Contract Research Organizations
      • 13.7.6.1.4 Academic and Research Institutes
    • 13.7.6.2 Segmentation By Deployment Mode
      • 13.7.6.2.1 Cloud-Based
      • 13.7.6.2.2 Hybrid
      • 13.7.6.2.3 On-Premise
    • 13.7.6.3 Segmentation By Application
      • 13.7.6.3.1 Clinical-Trial Design and Recruitment
      • 13.7.6.3.2 Drug Discovery and Lead Identification
      • 13.7.6.3.3 Lead Optimization
      • 13.7.6.3.4 Pharmacovigilance and Safety Monitoring
      • 13.7.6.3.5 Pre-clinical Development
      • 13.7.6.3.6 Manufacturing-Process Optimization
      • 13.7.6.3.7 Other Application
  • 13.7.7 Rest of LAMEA
    • 13.7.7.1 Segmentation By End User
      • 13.7.7.1.1 Large Pharmaceutical Companies
      • 13.7.7.1.2 Small and Mid-Size Biotech Firms
      • 13.7.7.1.3 Contract Research Organizations
      • 13.7.7.1.4 Academic and Research Institutes
    • 13.7.7.2 Segmentation By Deployment Mode
      • 13.7.7.2.1 Cloud-Based
      • 13.7.7.2.2 Hybrid
      • 13.7.7.2.3 On-Premise
    • 13.7.7.3 Segmentation By Application
      • 13.7.7.3.1 Clinical-Trial Design and Recruitment
      • 13.7.7.3.2 Drug Discovery and Lead Identification
      • 13.7.7.3.3 Lead Optimization
      • 13.7.7.3.4 Pharmacovigilance and Safety Monitoring
      • 13.7.7.3.5 Pre-clinical Development
      • 13.7.7.3.6 Manufacturing-Process Optimization
      • 13.7.7.3.7 Other Application

Chapter 14. Company Snapshot

• 14.1 InSilico Medicine
  • 14.1.1 Business Overview
  • 14.1.2 Key Information
  • 14.1.3 Company Focus
  • 14.1.4 Strategic Insights
  • 14.1.5 Strategy Deployed
  • 14.1.6 Product & Service Portfolio
  • 14.1.7 Capability Overview
  • 14.1.8 Technology & Innovation Focus
  • 14.1.9 Customers / End Users
  • 14.1.10 Competitive Positioning
  • 14.1.11 Key Differentiators
  • 14.1.12 Portfolio Matrix
  • 14.1.13 SWOT Analysis
  • 14.1.14 Future Outlook
• 14.2 Numerion Labs, Inc.
  • 14.2.1 Business Overview
  • 14.2.2 Key Information
  • 14.2.3 Company Focus
  • 14.2.4 Strategic Insights
  • 14.2.5 Strategy Deployed
  • 14.2.6 Product & Service Portfolio
  • 14.2.7 Capability Overview
  • 14.2.8 Technology & Innovation Focus
  • 14.2.9 Customers / End Users
  • 14.2.10 Competitive Positioning
  • 14.2.11 Key Differentiators
  • 14.2.12 Portfolio Matrix
  • 14.2.13 SWOT Analysis
  • 14.2.14 Future Outlook
• 14.3 BenevolentAI Group
  • 14.3.1 Business Overview
  • 14.3.2 Key Information
  • 14.3.3 Company Focus
  • 14.3.4 Strategic Insights
  • 14.3.5 Strategy Deployed
  • 14.3.6 Product & Service Portfolio
  • 14.3.7 Capability Overview
  • 14.3.8 Technology & Innovation Focus
  • 14.3.9 Customers / End Users
  • 14.3.10 Competitive Positioning
  • 14.3.11 Key Differentiators
  • 14.3.12 Portfolio Matrix
  • 14.3.13 SWOT Analysis
  • 14.3.14 Future Outlook
• 14.4 Shenzhen Jingtai Technology Co., Ltd (XtalPi)
  • 14.4.1 Business Overview
  • 14.4.2 Key Information
  • 14.4.3 Company Focus
  • 14.4.4 Strategic Insights
  • 14.4.5 Strategy Deployed
  • 14.4.6 Product & Service Portfolio
  • 14.4.7 Capability Overview
  • 14.4.8 Technology & Innovation Focus
  • 14.4.9 Customers / End Users
  • 14.4.10 Competitive Positioning
  • 14.4.11 Key Differentiators
  • 14.4.12 Portfolio Matrix
  • 14.4.13 SWOT Analysis
  • 14.4.14 Future Outlook
• 14.5 Recursion Pharmaceuticals, Inc.
  • 14.5.1 Business Overview
  • 14.5.2 Key Information
  • 14.5.3 Company Focus
  • 14.5.4 Strategic Insights
  • 14.5.5 Strategy Deployed
  • 14.5.6 Product & Service Portfolio
  • 14.5.7 Capability Overview
  • 14.5.8 Technology & Innovation Focus
  • 14.5.9 Customers / End Users
  • 14.5.10 Competitive Positioning
  • 14.5.11 Key Differentiators
  • 14.5.12 Portfolio Matrix
  • 14.5.13 SWOT Analysis
  • 14.5.14 Future Outlook
• 14.6 Deep Genomics Incorporated
  • 14.6.1 Business Overview
  • 14.6.2 Key Information
  • 14.6.3 Company Focus
  • 14.6.4 Strategic Insights
  • 14.6.5 Strategy Deployed
  • 14.6.6 Product & Service Portfolio
  • 14.6.7 Capability Overview
  • 14.6.8 Technology & Innovation Focus
  • 14.6.9 Customers / End Users
  • 14.6.10 Competitive Positioning
  • 14.6.11 Key Differentiators
  • 14.6.12 Portfolio Matrix
  • 14.6.13 SWOT Analysis
  • 14.6.14 Future Outlook
• 14.7 Schrodinger, LLC
  • 14.7.1 Business Overview
  • 14.7.2 Key Information
  • 14.7.3 Company Focus
  • 14.7.4 Strategic Insights
  • 14.7.5 Strategy Deployed
  • 14.7.6 Product & Service Portfolio
  • 14.7.7 Capability Overview
  • 14.7.8 Technology & Innovation Focus
  • 14.7.9 Customers / End Users
  • 14.7.10 Competitive Positioning
  • 14.7.11 Key Differentiators
  • 14.7.12 Portfolio Matrix
  • 14.7.13 SWOT Analysis
  • 14.7.14 Future Outlook
• 14.8 Owkin Inc.
  • 14.8.1 Business Overview
  • 14.8.2 Key Information
  • 14.8.3 Company Focus
  • 14.8.4 Strategic Insights
  • 14.8.5 Strategy Deployed
  • 14.8.6 Product & Service Portfolio
  • 14.8.7 Capability Overview
  • 14.8.8 Technology & Innovation Focus
  • 14.8.9 Customers / End Users
  • 14.8.10 Competitive Positioning
  • 14.8.11 Key Differentiators
  • 14.8.12 Portfolio Matrix
  • 14.8.13 SWOT Analysis
  • 14.8.14 Future Outlook
• 14.9 PeptiDream Inc.
  • 14.9.1 Business Overview
  • 14.9.2 Key Information
  • 14.9.3 Company Focus
  • 14.9.4 Strategic Insights
  • 14.9.5 Strategy Deployed
  • 14.9.6 Product & Service Portfolio
  • 14.9.7 Capability Overview
  • 14.9.8 Technology & Innovation Focus
  • 14.9.9 Customers / End Users
  • 14.9.10 Competitive Positioning
  • 14.9.11 Key Differentiators
  • 14.9.12 Portfolio Matrix
  • 14.9.13 SWOT Analysis
  • 14.9.14 Future Outlook
• 14.10 Healx Limited
  • 14.10.1 Business Overview
  • 14.10.2 Key Information
  • 14.10.3 Company Focus
  • 14.10.4 Strategic Insights
  • 14.10.5 Strategy Deployed
  • 14.10.6 Product & Service Portfolio
  • 14.10.7 Capability Overview
  • 14.10.8 Technology & Innovation Focus
  • 14.10.9 Customers / End Users
  • 14.10.10 Competitive Positioning
  • 14.10.11 Key Differentiators
  • 14.10.12 Portfolio Matrix
  • 14.10.13 SWOT Analysis
  • 14.10.14 Future Outlook

Chapter 15. Winning Imperatives of Agentic AI In Pharmaceuticals Market